Physician profile
Michael J Colin
NPI 1366504482
$9,329.71
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,883 · 2020: $1,082 · 2021: $1,818 · 2022: $1,280 · 2023: $125 · 2024: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,642.43 | 2019-2024 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $1,216.10 | 2021 | |
| Lilly USA, LLC | $1,054.96 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $772.43 | 2019-2022 | |
| Horizon Therapeutics Plc | $573.22 | 2019-2022 | |
| Pfizer INC. | $550.80 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $444.38 | 2019 | |
| Mallinckrodt Enterprises LLC | $413.45 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $381.68 | 2022 | |
| Janssen Biotech, INC. | $346.57 | 2019-2022 | |
| Ucb, INC. | $336.86 | 2019-2020 | |
| Abbvie INC. | $272.71 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $264.31 | 2020-2021 | |
| Glaxosmithkline, LLC. | $144.94 | 2019-2020 | |
| Genzyme Corporation | $140.06 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $130.54 | 2019-2020 | |
| Radius Health, INC. | $120.53 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $119.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $57.37 | 2019-2020 | |
| Genentech USA, INC. | $53.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.64 | 2019 | |
| Hikma Pharmaceuticals USA | $34.93 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $31.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $30.76 | 2019 | |
| Octapharma USA, INC. | $29.52 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.60 | 2019 | |
| Ironwood Pharmaceuticals, INC | $21.44 | 2019 | |
| Merck Sharp & Dohme LLC | $19.01 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.71 | 2020 | |
| Novo Nordisk INC | $17.31 | 2020 | |
| Allergan, INC. | $15.23 | 2020 | |
| Medexus Pharma, INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Colin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.